BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral GAAP and adjusted diluted […]
Other News
Teleflex Reports First Quarter Financial Results and Full Year 2023 Outlook
WAYNE, Pa., May 04, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended April 2, 2023. First quarter financial summary Revenues of $710.9 million, inclusive of five extra shipping days year-over-year, up 10.8% compared to the prior year period; up 13.2% on a […]
Clinical Trial Enrollment Complete for Study of MIVI Q™ Revascularization System that Treats Acute Ischemic Stroke
EDEN PRAIRIE, Minn., May 3, 2023 /PRNewswire/ — MIVI Neuroscience, Inc., innovator of next-generation neurointerventional medical devices, today announced that it has completed enrollment in the company’s clinical trial to assess the safety and effectiveness of the Q™ Revascularization System for the treatment of acute ischemic stroke (EVAQ Trial). The EVAQ Trial enrolled […]
MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA
GENEVA, May 4, 2023 /PRNewswire/ — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR™ in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been […]
Humacyte’s Human Acellular Vessel™ (HAV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma
HAV granted second RMAT designation by the FDA RMAT will support Humacyte’s lead indication in Vascular Trauma DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, has been recently granted the U.S. Food […]
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase Q1 2023 CAPLYTA total prescriptions increased 159%, versus the same period […]
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
– Gibson Dunn Files Amended Complaint with Powerful New Evidence – ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”) and filed an amended complaint against DSE in the […]
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million “As we look towards the remainder of the year, we will continue to focus on achieving our near-term milestones, including driving IBSRELA adoption, preparing to launch XPHOZAH in the second half of this year pending FDA approval, […]
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., May 04, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Roger Jeffs, […]
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
– Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023 – Positive results announced in Cohort 5 of Phase 2 PROPEL 2 trial […]
Recent
Galaxy Therapeutics Achieves CE Mark for SEAL™ Embolization System, Enabling Commercial Launch Across Europe and International Markets
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
Galaxy Therapeutics Achieves CE Mark for SEAL™ Embolization System, Enabling Commercial Launch Across Europe and International Markets
Popular
- No commented posts yet